My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
BSE: 524590 | NSE: | Pharmaceuticals & Drugs | Small Cap
1. Is Hemo Organic Ltd a good quality company?
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Hemo Organic Ltd is a below average quality company.
2. Is Hemo Organic Ltd undervalued or overvalued?
The key valuation ratios of Hemo Organic Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Hemo Organic Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Hemo Organic Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | -10.3% | -6.8% | -7.5% | -38.4% | -19.2% | -39.9% | -43.1% | -11.9% | -44.1% | -89.3% | - | ||
| Value Creation Index ⓘ | -1.7 | -1.5 | -1.5 | -3.7 | -2.4 | -3.9 | -4.1 | -1.9 | -4.2 | -7.4 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 0.6 | 0.7 | 0.2 | 0.1 | 0.6 | 0.1 | 0.1 | 0.3 | 0 | 0 | 0 | ||
| YoY Gr. Rt. % | - | 24.6% | -77.5% | -31.3% | 445.5% | -85% | -44.4% | 460% | -96.4% | 0% | - | ||
| Adj EPS ⓘ | -0.7 | -0.4 | -0.3 | -0.9 | -0.2 | -0.4 | -0.4 | -0.1 | -0.1 | -0.2 | -0.2 | ||
| YoY Gr. Rt. % | - | NA | NA | NA | NA | NA | NA | NA | NA | NA | - | ||
| BVPS (₹) ⓘ | 4.2 | 4.4 | 3.7 | 1.2 | 1.2 | 0.7 | 0.4 | 0.3 | 0.2 | 0 | -0.2 | ||
| Adj Net Profit ⓘ | -0.2 | -0.1 | -0.1 | -0.3 | -0.1 | -0.2 | -0.1 | 0 | -0.1 | -0.1 | 0 | ||
| Cash Flow from Ops. ⓘ | -0.4 | 0.1 | 0.1 | -0.8 | -0.2 | -0.1 | 0 | 0 | 0 | 0 | - | ||
| Debt/CF from Ops. ⓘ | -0.7 | 0.7 | 0.7 | 0 | 0 | -0.7 | -2 | 0.3 | -2.6 | -7.9 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | -36.2% | -55.9% | -41.5% | 0% | ||||||||
| Adj EPS ⓘ | NA | NA | NA | NA | ||||||||
| BVPSⓘ | -48.9% | -61.4% | -70.5% | -94.7% | ||||||||
| Share Price | -2.3% | -14.6% | -18.5% | -72.5% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | -13 | -8.4 | -7.8 | -39.5 | -19.2 | -44.9 | -61.4 | -17.5 | -53.4 | -180.2 | 228.6 | |
| Op. Profit Mgn % ⓘ | 14.1 | -11 | -38.4 | -50.2 | -13.1 | -170.4 | -219.7 | -6.8 | -591.5 | -909.8 | NAN | |
| Net Profit Mgn % ⓘ | -41.4 | -17.2 | -66.7 | -294.8 | -13.1 | -170.3 | -219.7 | -7.9 | -593.2 | -913.2 | -INF | |
| Debt to Equity ⓘ | 0.2 | 0 | 0 | 0 | 0 | 0.3 | 0.6 | 0 | 0.5 | 10.2 | - | |
| Working Cap Days ⓘ | 387 | 169 | 699 | 881 | 368 | 3,622 | 5,397 | 570 | 3,490 | 4,395 | 0 | |
| Cash Conv. Cycle ⓘ | 171 | 118 | 483 | 251 | 61 | 1,002 | 1,569 | -133 | 2,410 | 3,301 | 0 | |
Return on Equity has increased versus last 3 years average to 228.60%
Sales growth has been subdued in last 3 years -41.52%
Debt to equity has increased versus last 3 years average to 10.21
Sales growth is not so good in last 4 quarters at -25.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -0.2 | - |
| TTM Sales (₹ Cr.) | 0 | - |
| BVPS (₹.) ⓘ | -0.2 | - |
| Reserves (₹ Cr.) ⓘ | -4 | - |
| P/BV ⓘ | -42.20 | - |
| PE ⓘ | 0.00 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 5.57 / 25.20 |
| All Time Low / High (₹) | 0.50 / 140.40 |
| Market Cap (₹ Cr.) | 2.2 |
| Equity (₹ Cr.) | 3.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 41.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dinesh Allorga incorporated as public limited Company in August 1992. It is engaged in production and sale of ayurvedic medicines and chemicals.
The registered office is located at 8-A, Gulnar Chinar-Gulnar Apartment, V V Nagar Road, Anand, Gujrat - 388001.
The company has posted net profit of Rs 0.04 crore during the quarter ended June 2011 against the break-even during quarter ended June 2010.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
